Medicine benefits remain one of the clearest ways members feel the value of their medical scheme, according to the 2025 Mediscor Medicines Review. The report describes not runaway growth but steady pressure from utilisation, high-cost therapies, chronic disease and member affordability. The analysis draws on fee-for-service schemes with ongoing Mediscor PBM contracts, covering more than 1 million beneficiaries. Year-on-year shifts,…